DekaBank Deutsche Girozentrale Sells 411 Shares of Agilent Technologies, Inc. $A

DekaBank Deutsche Girozentrale lessened its stake in Agilent Technologies, Inc. (NYSE:A) by 0.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 168,135 shares of the medical research company’s stock after selling 411 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Agilent Technologies were worth $20,132,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Agilent Technologies by 13.5% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company’s stock valued at $4,279,000 after acquiring an additional 4,362 shares during the last quarter. Alps Advisors Inc. increased its holdings in Agilent Technologies by 29.5% during the 1st quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company’s stock valued at $1,563,000 after purchasing an additional 3,040 shares during the period. D.A. Davidson & CO. increased its holdings in Agilent Technologies by 30.4% during the 1st quarter. D.A. Davidson & CO. now owns 9,474 shares of the medical research company’s stock valued at $1,108,000 after purchasing an additional 2,207 shares during the period. LGT Capital Partners LTD. increased its holdings in Agilent Technologies by 7.6% during the 1st quarter. LGT Capital Partners LTD. now owns 768,252 shares of the medical research company’s stock valued at $89,870,000 after purchasing an additional 54,302 shares during the period. Finally, Live Oak Investment Partners purchased a new position in Agilent Technologies during the 1st quarter valued at about $603,000.

Agilent Technologies Stock Up 0.2%

A stock opened at $146.01 on Thursday. Agilent Technologies, Inc. has a fifty-two week low of $96.43 and a fifty-two week high of $153.84. The business’s 50 day moving average price is $129.24 and its two-hundred day moving average price is $118.56. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.71 and a current ratio of 2.25. The company has a market capitalization of $41.39 billion, a price-to-earnings ratio of 34.27, a price-to-earnings-growth ratio of 4.76 and a beta of 1.26.

Agilent Technologies (NYSE:A) last posted its earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.37. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The firm had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.67 billion. During the same quarter in the prior year, the business earned $1.32 EPS. The business’s revenue for the quarter was up 10.1% on a year-over-year basis. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, analysts forecast that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 22nd. Investors of record on Tuesday, September 30th were paid a $0.248 dividend. The ex-dividend date was Tuesday, September 30th. This represents a $0.99 annualized dividend and a dividend yield of 0.7%. Agilent Technologies’s dividend payout ratio is presently 23.24%.

Analysts Set New Price Targets

A number of brokerages recently issued reports on A. Barclays boosted their price target on Agilent Technologies from $125.00 to $150.00 and gave the company an “equal weight” rating in a report on Thursday, October 2nd. Rothschild & Co Redburn began coverage on Agilent Technologies in a report on Wednesday, October 8th. They set a “buy” rating and a $165.00 price target on the stock. Evercore ISI boosted their price target on Agilent Technologies from $128.00 to $140.00 and gave the company an “in-line” rating in a report on Tuesday, October 7th. UBS Group upgraded Agilent Technologies from a “neutral” rating to a “buy” rating and boosted their price target for the company from $130.00 to $170.00 in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $149.62.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.